Structural basis of human LRG1 recognition by Magacizumab, a humanized monoclonal antibody with therapeutic potential. Issue 6 (9th May 2022)

• Record Type: Journal Article
• Authors: Gutiérrez-Fernández, Javier; Javaid, Faiza; De Rossi, Giulia; Chudasama, Vijay; Greenwood, John; Moss, Stephen E.; Luecke, Hartmut
• Is Part Of: Acta crystallographica. Volume 78:Issue 6(2022)
• Page Start: 725
• Page End: 734
• Publication Date: 2022-05-09
• Subjects: cancer immunotherapy -- leucine‐rich α‐2‐glycoprotein 1 -- Magacizumab -- angiogenesis -- antibody–antigen complex; X-ray crystallography -- Periodicals; Crystallography -- Periodicals; Molecular biology -- Periodicals; Molecular structure -- Periodicals; Biomolecules -- Structure -- Periodicals; Cytology -- Periodicals; Biomolecules -- Structure; Crystallography; Cytology; Molecular biology; Molecular structure; X-ray crystallography; Periodicals; 548
• DOI: 10.1107/S2059798322004132
• Languages: English
• ISSNs: 2059-7983

Abstract

Abstract : Structural interactions between the LRG1 epitope and the Fab fragment of Magacizumab determine its specific binding mode and the key residues involved in LRG1 recognition. Abstract : The formation of new dysfunctional blood vessels is a crucial stage in the development of various conditions such as macular degeneration, diabetes, cardiovascular disease, neurological disease and inflammatory disorders, as well as during tumor growth, eventually contributing to metastasis. An important factor involved in pathogenic angiogenesis is leucine‐rich α‐2‐glycoprotein 1 (LRG1), the antibody blockade of which has been shown to lead to a reduction in both choroidal neovascularization and tumor growth in mouse models. In this work, the structural interactions between the LRG1 epitope and the Fab fragment of Magacizumab, a humanized function‐blocking IgG4 against LRG1, are analysed, determining its specific binding mode and the key residues involved in LRG1 recognition. Based on these structural findings, a series of mutations are suggested that could be introduced into Magacizumab to increase its affinity for LRG1, as well as a model of the entire Fab–LRG1 complex that could enlighten new strategies to enhance affinity, consequently leading towards an even more efficient therapeutic.